Samyang Biopharm Corporation
Financials
Valuation Metrics
Samyang Biopharm Corporation's Market Cap is ₩3636B. Ranked #573 of 2,421 in KR market (top 24%), #346 of 781 on KOSPI (top 44%), #60 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 363.61B KRW | KR#573/2,421 Sec#60/231 |
| Revenue | 28.59B KRW | KR#2,043/2,421 Sec#141/231 |
| Net Income | 2.24B KRW | KR#1,393/2,421 Sec#97/231 |
| Total Assets | 339.28B KRW | KR#969/2,421 Sec#60/231 |
| Net Assets | 234.73B KRW | KR#859/2,421 Sec#57/231 |
| Value | ||
| P/E | 162.58x | KR#1,515/2,421 Sec#104/231 |
| P/B | 1.55x | KR#1,787/2,421 Sec#125/231 |
| P/S | 12.72x | KR#2,299/2,421 Sec#169/231 |
| EV/EBITDA | 153.00x | KR#1,520/2,421 Sec#104/231 |
| FCF Yield | 0.84% | KR#1,149/2,421 Sec#83/231 |
| Profitability | ||
| ROE | 0.95% | KR#1,486/2,421 Sec#103/231 |
| ROA | 0.66% | KR#1,450/2,421 Sec#102/231 |
| Op. Margin | 9.41% | KR#563/2,421 Sec#47/231 |
| Financial Health | ||
| Debt Ratio | 44.54% | KR#878/2,421 Sec#101/231 |
| Total Debt | 77.82B KRW | KR#821/2,421 Sec#51/231 |
| FCF | 3.05B KRW | KR#1,018/2,421 Sec#72/231 |
| Cash | 29.68B KRW | KR#1,015/2,421 Sec#70/231 |
| Current Ratio | 1.68x | KR#1,050/2,421 Sec#119/231 |
| Net Debt/EBITDA | 17.89x | KR#1,352/2,421 Sec#96/231 |
| Performance | ||
| 1M Return | 12.93% | KR#383/2,421 Sec#25/231 |
| From 52W High | -67.59% | KR#2,134/2,421 Sec#178/231 |
| 1Y MDD | -76.24% | KR#2,215/2,421 Sec#197/231 |
| Trading | ||
| Volume | 28,961 shares | KR#1,397/2,421 Sec#137/231 |
| Trading Value | 1.42B KRW | KR#634/2,421 Sec#64/231 |
| Foreign Own. | 2.84% | KR#1,339/2,421 Sec#121/231 |
| Per Share | ||
| EPS | 301 KRW | KR#1,175/2,421 Sec#80/231 |
| BPS | 31,568 KRW | KR#355/2,421 Sec#24/231 |
Company Info
Samyang Biopharm is a company operating in the pharmaceutical bio business, newly established through a spin-off from Samyang Holdings. It develops new drugs and improved new drugs based on innovative technologies, including drug delivery platforms (DDS), polymer nanoparticle technology, and siRNA/mRNA-based delivery technology. The company holds the top position in the domestic cytotoxic anticancer drug market (with Genexol, Pemed) and the global biodegradable suture thread market, demonstrating high technological capabilities and market share. Samyang Biopharm was established in 2025 and is headquartered in Seongnam-si, Gyeonggi-do.